Brown AND Burk Philippines Inc

Brown & Burk Philippines Inc. is a privately held pharmaceutical company headquartered in Makati City, Metro Manila, Philippines. Established on May 23, 2005, the company is dedicated to the professional and profitable distribution of pharmaceutical products within the country. Its mission is to provide Filipinos with international-quality medicines manufactured at US-FDA facilities, ensuring affordability and accessibility. The company emphasizes values such as integrity, excellence, discipline, fairness, and respect in its operations.

Brown & Burk Philippines Inc. operates as a pharmaceutical importer and distributor, focusing on branded generic pharmaceuticals. It collaborates with manufacturers like Micro Labs Limited, an Indian multinational pharmaceutical company, to source its product portfolio. The company markets its products to various healthcare professionals, including internists, family practitioners, general practitioners, psychiatrists, neurologists, gastroenterologists, endocrinologists, cardiologists, and specialists in otolaryngology, gynecology, and dermatology across the Philippines. (philjobnet.gov.ph)

Brown & Burk Philippines Inc. operates from its headquarters located at Unit 501, SEDCCO I Building, 120 Rada Street, Legaspi Village, Makati City, Metro Manila. (philjobnet.gov.ph) The company collaborates with distribution partners, such as RBC-MDC Corporation, to ensure its products reach a wide network of healthcare facilities, including leading chain pharmacies, independent pharmacies, private and government hospitals, and medical centers across the Philippines. (philjobnet.gov.ph) While specific details about its logistics capabilities and geographic coverage beyond the Philippines are not publicly disclosed, the company's extensive distribution network within the country indicates a robust logistics framework.

In the Philippines' pharmaceutical supply chain, Brown & Burk Philippines Inc. functions primarily as a pharmaceutical importer and distributor. By sourcing branded generic pharmaceuticals from manufacturers like Micro Labs Limited, the company plays a crucial role in making these products accessible to a broad spectrum of healthcare providers and patients across the nation. Its focus on branded generics allows it to offer cost-effective alternatives to branded drugs, thereby enhancing the affordability and availability of essential medications in the Philippine market.

Brown & Burk Philippines Inc. demonstrates a high degree of supplier concentration, sourcing its pharmaceutical products exclusively from Micro Labs Limited. This single-source dependency could pose risks related to supply chain disruptions, such as production delays or quality control issues. However, the company's consistent importation of 25 shipments valued at $888,000 USD over the period from 2022 to 2026 suggests a stable and ongoing relationship with Micro Labs Limited. The substantial import value and frequency of shipments indicate a strong and reliable partnership, which may mitigate potential risks associated with supplier concentration.

The resilience of Brown & Burk Philippines Inc.'s supply chain is closely tied to its exclusive sourcing from Micro Labs Limited. While this concentrated sourcing strategy may expose the company to risks associated with supply chain disruptions, such as production delays or quality control issues, the consistent importation of 25 shipments valued at $888,000 USD over the period from 2022 to 2026 suggests a stable and ongoing relationship with Micro Labs Limited. This stability may help mitigate potential risks associated with supplier concentration. However, the lack of publicly available information regarding backup suppliers, formulation diversity, shipping route exposure, and the regulatory compliance status of Micro Labs Limited's facilities limits a comprehensive assessment of the supply chain's overall resilience.

The sourcing pattern of Brown & Burk Philippines Inc., characterized by exclusive procurement from Micro Labs Limited, positions the company as a significant player in the branded generic pharmaceutical market within the Philippines. This strategic choice allows the company to offer a focused product portfolio, potentially enhancing brand recognition and operational efficiency. For Indian exporters seeking to become alternative suppliers, this presents an opportunity to diversify Brown & Burk's product offerings and reduce dependency on a single supplier. Establishing a relationship with Brown & Burk could involve demonstrating compliance with the Philippines' regulatory standards and offering competitive pricing to meet the company's quality and affordability criteria.

In the Philippines, the Food and Drug Administration (FDA) is the primary regulatory body overseeing the importation, registration, and distribution of pharmaceutical products. The FDA operates under the Department of Health (DOH) and is responsible for ensuring the safety, efficacy, and quality of health products entering the country. Key legislation governing pharmaceutical imports includes the FDA Act of 2009 (Republic Act No. 9711) and the Food, Drugs, and Devices Act (Republic Act No. 3720). These laws establish the FDA's authority to regulate all health products, issue permits, licenses, and product registrations, and enforce standards for pharmaceutical imports. (respicio.ph)

Import licensing requirements in the Philippines stipulate that all pharmaceutical products must be registered with the FDA before they can be imported, sold, or distributed. The FDA requires a valid License to Operate (LTO) for importers and a Certificate of Good Manufacturing Practice (GMP) Compliance for manufacturers. GMP certificates from recognized authorities, such as the European Union (EU), World Health Organization (WHO), and Pharmaceutical Inspection Co-operation Scheme (PIC/S), are generally accepted by the FDA. Additionally, importers must secure the necessary import permits and clearances from the Bureau of Customs (BOC) prior to importation. (respicio.ph)

Pharmaceutical products imported into the Philippines must comply with the FDA's quality standards, which include batch testing and stability requirements to ensure product safety and efficacy. Labeling must adhere to FDA guidelines, which typically require information such as the product's generic and brand names, dosage strength, dosage form, manufacturer's details, and importer's information. Labels must be in English and Filipino, and include the phrase "Imported by [importer's name]" and the suggested retail price. Serialization mandates may apply to facilitate traceability and prevent counterfeit products, though specific requirements can vary. (respicio.ph)

Between 2024 and 2026, the Philippines FDA has implemented several regulatory changes affecting pharmaceutical imports. Notably, in August 2024, the FDA issued Administrative Order No. 2024-0012, outlining regulations for registering pharmaceutical products and Active Pharmaceutical Ingredients (APIs) intended exclusively for export. This order sets forth guidelines, requirements, and procedures for the registration process of export-only pharmaceutical products and APIs. Additionally, in November 2025, the Philippines published two new pharmaceutical regulations: the Implementing Guidelines of the WHO Collaborative Procedure on the Registration of Pharmaceutical Products Approved by Stringent Regulatory Authorities (SRAs) and the Classification of Pharmaceutical Products Intended for Human Use. These regulations aim to streamline the registration process and enhance the availability of essential medicines in the local market.

Brown & Burk Philippines Inc. focuses on therapeutic areas such as psychiatry, neurology, cardiology, endocrinology, antibiotics and analgesics, gastroenterology, and ophthalmology. This strategic focus aligns with the company's mission to provide Filipinos with international-quality medicines manufactured at US-FDA facilities at affordable prices. The emphasis on these therapeutic areas is driven by the market demand for effective treatments in these specialties, addressing prevalent health conditions in the Philippines. By concentrating on these segments, the company aims to meet the needs of healthcare professionals and patients, thereby enhancing its market presence and impact.

Brown & Burk Philippines Inc. employs a sourcing strategy that focuses on branded generic pharmaceuticals, primarily procuring products from Micro Labs Limited, an Indian multinational pharmaceutical company. This approach allows the company to offer cost-effective alternatives to branded drugs, enhancing the affordability and accessibility of essential medications in the Philippine market. The preference for branded generics aligns with the company's mission to provide international-quality medicines at affordable prices, ensuring that patients receive effective treatments without the high costs associated with branded pharmaceuticals.

Based on its product mix, Brown & Burk Philippines Inc. serves multiple segments of the Philippine pharmaceutical market, including retail pharmacies, hospitals, government tenders, and wholesale distribution. By offering a range of branded generic pharmaceuticals across various therapeutic areas, the company caters to the diverse needs of healthcare providers and patients. Its strategic focus on affordability and quality positions it as a key player in enhancing the accessibility of essential medications across the country.

There is a realistic opportunity for new Indian suppliers to collaborate with Brown & Burk Philippines Inc. to diversify its product offerings and reduce dependency on a single supplier. Establishing a relationship with Brown & Burk could involve demonstrating compliance with the Philippines' regulatory standards and offering competitive pricing to meet the company's quality and affordability criteria